Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial
Stephan Weidinger(University Hospital Schleswig-Holstein), Ben Porter‐Brown(Sanofi (United Kingdom)), Thomas Bieber(CK-CARE), John T. O’Malley(Brigham and Women's Hospital), Michael J. Cork(Royal Hallamshire Hospital), Nuala Brennan(Kymab (United Kingdom)), Sally Gilbert(Sanofi (United Kingdom)), Adam Reich(Rzeszów University of Technology), Marisa Stebegg(Sanofi (Germany)), Rosamund Wilson, Sonia Quaratino(Kymab (United Kingdom))
Cited by 105
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1
|Nature Genetics|2010|1.1k
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
|Nature Genetics|2012|1k
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Epidermal Barrier Dysfunction in Atopic Dermatitis
|Journal of Investigative Dermatology|2009|756